Cases & Deals

REGENXBIO successfully blocks institution of post-grant review of gene therapy patent

Client(s) REGENXBIO Inc.

Jones Day successfully defended REGENXBIO, Inc. against a post-grant review (PGR) petition filed by Passage Bio before the U.S. Patent Trial and Appeal Board (PTAB) against one of REGENXBIO's AAV9 patents. The PTAB denied institution of the review.

Passage Bio, Inc. v. Trustees of the University of Pennsylvania et al., PGR2021-00073 (PTAB)